US equities |
SPCX $166.85 ▲+4.96% NVDA $236.15 ▲+0.94% MU $1,062.71 ▼-1.13% TSLA $377.60 ▲+1.89% MSFT $524.61 ▲+1.37% SNDK $1,705.18 ▼-0.86% INTC $117.20 ▼-1.79% META $742.52 ▲+1.98%
FinancialContent

Evolus, Inc. - Common Stock (NQ:EOLS)

7.350 +0.210 (+2.94%)
Delayed Quote Updated: 12:21 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
From Evolus
Via Business Wire
News headline image
Evolus to Report Second Quarter Financial Results on August 5, 2025
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Assessing Evolus: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolysse™ Recognized in 2025 Shape Skin Awards
From Evolus
Via Business Wire
News headline image
Breaking Down Evolus: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Evolus Announces Departure of its Chief Financial Officer
From Evolus
Via Business Wire
News headline image
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
What Analysts Are Saying About Evolus Stock ↗
 
Via Benzinga
News headline image
Evolus Reports First Quarter 2025 Results
From Evolus
Via Business Wire
News headline image
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
From Evolus
Via Business Wire
News headline image
Evolus to Report First Quarter Financial Results on May 7, 2025
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Evolus Announces Commercial Launch of Evolysse™
From Evolus
Via Business Wire
News headline image
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
News headline image
Breaking Down Evolus: 8 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas ↗
There's a lot going on for investors. 
Via The Motley Fool
News headline image
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
From Evolus
Via Business Wire
News headline image
Earnings Scheduled For March 4, 2025 ↗
 
Via Benzinga
News headline image
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
From Evolus
Via Business Wire
News headline image
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
From Evolus
Via Business Wire
News headline image
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
From Evolus
Via Business Wire
News headline image
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >